WO2003055526A3 - Erythropoietin conjugates - Google Patents

Erythropoietin conjugates Download PDF

Info

Publication number
WO2003055526A3
WO2003055526A3 PCT/DK2002/000871 DK0200871W WO03055526A3 WO 2003055526 A3 WO2003055526 A3 WO 2003055526A3 DK 0200871 W DK0200871 W DK 0200871W WO 03055526 A3 WO03055526 A3 WO 03055526A3
Authority
WO
WIPO (PCT)
Prior art keywords
erythropoietin
polypeptide
erythropoietin conjugates
conjugates
epo
Prior art date
Application number
PCT/DK2002/000871
Other languages
French (fr)
Other versions
WO2003055526A2 (en
Inventor
Kim Vilbour Andersen
Original Assignee
Maxygen Aps
Maxygen Holdings Ltd
Kim Vilbour Andersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Aps, Maxygen Holdings Ltd, Kim Vilbour Andersen filed Critical Maxygen Aps
Priority to AU2002351746A priority Critical patent/AU2002351746A1/en
Publication of WO2003055526A2 publication Critical patent/WO2003055526A2/en
Publication of WO2003055526A3 publication Critical patent/WO2003055526A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule

Abstract

The invention relates to polypeptide conjugates exhibiting erythropoietin (EPO) activity, comprising at least one polymer molecule, preferably polyethylene glycol, covalently attached to an attachment site of a polypeptide, e.g. a lysine or cysteine residue or a carbohydrate chain.
PCT/DK2002/000871 2001-12-21 2002-12-18 Erythropoietin conjugates WO2003055526A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002351746A AU2002351746A1 (en) 2001-12-21 2002-12-18 Erythropoietin conjugates

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34350101P 2001-12-21 2001-12-21
DKPA200101953 2001-12-21
US60/343,501 2001-12-21
DKPA200101953 2001-12-21

Publications (2)

Publication Number Publication Date
WO2003055526A2 WO2003055526A2 (en) 2003-07-10
WO2003055526A3 true WO2003055526A3 (en) 2003-12-11

Family

ID=26069119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000871 WO2003055526A2 (en) 2001-12-21 2002-12-18 Erythropoietin conjugates

Country Status (2)

Country Link
AU (1) AU2002351746A1 (en)
WO (1) WO2003055526A2 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008500275A (en) * 2003-12-31 2008-01-10 セントカー・インコーポレーテツド Novel recombinant protein having an N-terminal free thiol
US7714114B2 (en) * 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
ATE467642T1 (en) 2006-07-25 2010-05-15 Lipoxen Technologies Ltd DERIVATIZATION OF GRANULOCYTE COLONEY-STIMULATING FACTOR
CA2659990C (en) 2006-08-04 2016-03-22 Prolong Pharmaceuticals, Inc. Polyethylene glycol erythropoietin conjugates
JP2010510794A (en) * 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド Modified erythropoietin polypeptide and therapeutic use thereof
US8383114B2 (en) 2007-09-27 2013-02-26 Amgen Inc. Pharmaceutical formulations
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
EP2574628B1 (en) 2008-01-25 2015-05-20 Amgen Inc. Ferroportin antibodies and methods of use
EP2294087B1 (en) 2008-05-01 2014-05-14 Amgen, Inc. Anti-hepcidin antibodies and methods of use
KR101275950B1 (en) * 2008-05-29 2013-06-25 한올바이오파마주식회사 Modified erythropoietin (epo) polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof
CN102215869B (en) 2008-11-13 2015-05-13 通用医疗公司 Methods and compositions for regulating iron homeostasis by modulation BMP-6
CA2778105C (en) 2009-10-23 2019-04-02 Amgen Inc. Vial adapter and system
FI2575935T4 (en) 2010-06-07 2023-11-23 Amgen Inc Drug delivery device
US9732132B2 (en) 2011-01-14 2017-08-15 Vanderbilt University Therapeutic compositions and methods for disorders associated with neuronal degeneration
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
US10092706B2 (en) 2011-04-20 2018-10-09 Amgen Inc. Autoinjector apparatus
EP3045188B1 (en) 2011-10-14 2020-12-23 Amgen Inc. Injector and method of assembly
CA2884887C (en) 2012-11-21 2023-09-12 Amgen Inc. Drug delivery device including insertion member and reservoir
BR112015022123B1 (en) 2013-03-15 2022-08-09 Intrinsic Lifesciences, Llc ANTIBODIES, ANTIGEN-BINDING FRAGMENTS OF SPECIFICALLY BINDING HEPCIDIN OR A HEPCIDIN PEPTIDE, USE, CONTAINING MEDIUM AND KIT
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
EP3593839A1 (en) 2013-03-15 2020-01-15 Amgen Inc. Drug cassette
BR112015024282B1 (en) 2013-03-22 2022-05-17 Amgen Inc Injector and injector mounting method
AU2014340171B2 (en) 2013-10-24 2019-05-30 Amgen Inc. Injector and method of assembly
EP3060281B1 (en) 2013-10-24 2019-01-30 Amgen Inc. Drug delivery system with temperature-sensitive control
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
WO2015171777A1 (en) 2014-05-07 2015-11-12 Amgen Inc. Autoinjector with shock reducing elements
CN106488782B (en) 2014-06-03 2021-03-09 安姆根有限公司 Device and method for assisting a user of a drug delivery device
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AU2015332557B2 (en) 2014-10-14 2020-05-14 Amgen Inc. Drug injection device with visual and audio indicators
WO2016100055A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with live button or user interface field
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
JP2018512184A (en) 2015-02-27 2018-05-17 アムジエン・インコーポレーテツド Drug delivery device having needle guard mechanism capable of adjusting threshold of resistance to movement of needle guard
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
ES2755717T3 (en) 2015-12-09 2020-04-23 Amgen Inc Autoinjector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
ES2814287T3 (en) 2016-03-15 2021-03-26 Amgen Inc Reduce the likelihood of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
CA3018426A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018152073A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
MX2019010544A (en) 2017-03-06 2019-10-21 Amgen Inc Drug delivery device with activation prevention feature.
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
MX2019010671A (en) 2017-03-09 2019-10-21 Amgen Inc Insertion mechanism for drug delivery device.
WO2018172219A1 (en) 2017-03-20 2018-09-27 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
MX2019011416A (en) 2017-03-28 2019-11-01 Amgen Inc Plunger rod and syringe assembly system and method.
MX2019014615A (en) 2017-06-08 2020-02-07 Amgen Inc Torque driven drug delivery device.
EP3634539A1 (en) 2017-06-08 2020-04-15 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
MA49461A (en) 2017-06-23 2020-04-29 Amgen Inc ELECTRONIC DRUG DELIVERY DEVICE INCLUDING A CAP ACTIVATED BY A SWITCH ASSEMBLY
JP7408398B2 (en) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド Needle insertion and retraction system with dual torsion spring system
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
JP7242562B2 (en) 2017-07-25 2023-03-20 アムジエン・インコーポレーテツド Drug delivery device with container access system and associated method of assembly
EP4085942A1 (en) 2017-07-25 2022-11-09 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49838A (en) 2017-08-09 2020-06-17 Amgen Inc DRUG DELIVERY SYSTEM WITH CHAMBER HYDRAULIC-PNEUMATIC PRESSURE
US11077246B2 (en) 2017-08-18 2021-08-03 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
MA50611A (en) 2017-10-04 2020-08-12 Amgen Inc FLOW ADAPTER FOR A DRUG DELIVERY DEVICE
EP3691716B1 (en) 2017-10-06 2023-11-29 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
EP3694578A1 (en) 2017-10-09 2020-08-19 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
JP2021501616A (en) 2017-11-06 2021-01-21 アムジエン・インコーポレーテツド Drug delivery device with placement and flow detection
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
JP7247174B2 (en) 2017-11-10 2023-03-28 アムジエン・インコーポレーテツド plunger for drug delivery device
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
CA3084486A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
CN112469454B (en) 2018-07-24 2024-01-26 安进公司 Delivery device for administering a drug
MX2021000749A (en) 2018-07-24 2021-03-29 Amgen Inc Delivery devices for administering drugs.
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MA53320A (en) 2018-07-31 2021-11-03 Amgen Inc FLUID PATH ASSEMBLY FOR DRUG DELIVERY DEVICE
MA53724A (en) 2018-09-24 2021-12-29 Amgen Inc INTERVENTIONAL DOSING SYSTEMS AND METHODS
IL281469B1 (en) 2018-09-28 2024-04-01 Amgen Inc Muscle wire escapement activation assembly for a drug delivery device
AR116679A1 (en) 2018-10-02 2021-06-02 Amgen Inc INJECTION SYSTEMS FOR THE ADMINISTRATION OF DRUGS WITH INTERNAL FORCE TRANSMISSION
EP3860686A1 (en) 2018-10-05 2021-08-11 Amgen Inc. Drug delivery device having dose indicator
KR20210076935A (en) 2018-10-15 2021-06-24 암젠 인크 Drug delivery device with damping mechanism
TW202031306A (en) 2018-10-15 2020-09-01 美商安進公司 Platform assembly process for drug delivery device
WO2020092056A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial needle retraction
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MA54048A (en) 2018-11-01 2022-02-09 Amgen Inc DRUG DELIVERY DEVICES WITH PARTIAL RETRACTION OF DRUG DELIVERY BODY
JP2022529319A (en) 2019-04-24 2022-06-21 アムジエン・インコーポレーテツド Syringe sterility confirmation assembly and method
JP2022545227A (en) 2019-08-23 2022-10-26 アムジエン・インコーポレーテツド Drug delivery device with configurable needle shield-engaging component and related methods
EP4341161A1 (en) 2021-05-21 2024-03-27 Amgen Inc. Method of optimizing a filling recipe for a drug container

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
WO1990012874A2 (en) * 1989-04-21 1990-11-01 Genetics Institute, Inc. Cysteine added variants of polypeptides and chemical modifications thereof
WO1994017784A1 (en) * 1993-02-04 1994-08-18 Amgen Inc. Pulmonary administration of erythropoietin
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2001002017A2 (en) * 1999-07-02 2001-01-11 F. Hoffmann-La Roche Ag Erythropoietin conjugates with polyethylenglycol
WO2001076640A2 (en) * 2000-04-07 2001-10-18 Amgen Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
WO1990012874A2 (en) * 1989-04-21 1990-11-01 Genetics Institute, Inc. Cysteine added variants of polypeptides and chemical modifications thereof
WO1994017784A1 (en) * 1993-02-04 1994-08-18 Amgen Inc. Pulmonary administration of erythropoietin
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2001002017A2 (en) * 1999-07-02 2001-01-11 F. Hoffmann-La Roche Ag Erythropoietin conjugates with polyethylenglycol
WO2001076640A2 (en) * 2000-04-07 2001-10-18 Amgen Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods

Also Published As

Publication number Publication date
AU2002351746A8 (en) 2003-07-15
WO2003055526A2 (en) 2003-07-10
AU2002351746A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
WO2003055526A3 (en) Erythropoietin conjugates
AU2001290312A1 (en) Peg-modified erythropoietin
DK1454138T3 (en) Immunocytokines with modulated selectivity
ES2172864T3 (en) 2-FUNGICIDE METOXIBENZOPHENONES.
NO20023315D0 (en) G-CSF conjugates
BR0210708B1 (en) drilling shaft deflection assembly.
WO2004108070A3 (en) Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2006053299A3 (en) Site-directed modification of fviii
BR9804214A (en) Compounds.
AU1316092A (en) Polyethylene protein conjugates
AU1392199A (en) Low-ph, acid-containing personal care compositions which exhibit reduced sting
DE60213276D1 (en) 1,2,4-thiadiazolium compounds as melanocortinreceptor modulators
BR8707431A (en) ASTEROID CONJUGATES
IT1311977B1 (en) REPELLENT HYDRO-OIL COMPOSITIONS.
AU5562600A (en) Integrated optics beam deflectors
ATE339896T1 (en) BIODEGRADABLE CHEWING GUM BASE
PT1975164E (en) Octahydrobenzimidazolone compounds as analgetics
HUP0102671A3 (en) Immunosupressive pharmaceutical compositions containing 2',2'-difluoro-nucleoside analogues
WO2002072010A3 (en) Taxane prodrugs
DE60210598D1 (en) 3,7-DIAZABICYCLOc3.3.1Ü FORMULATIONS AS ANTIARRHYTHMIKA
WO2002060929A3 (en) Polymer conjugates of neublastin and methods of using same
BR0103563B1 (en) swing arm assembly.
EP0990635A4 (en) Hydroxycyclopentanone
SE9904404D0 (en) Novel composition
DE60029084D1 (en) NEW DEPSIPEPTID CONNECTION

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP